These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 1942594

  • 21. Malignant hemangioendothelioma.
    Ihda H, Tokura Y, Fushimi M, Yokote R, Hashizume H, Shirahama S, Iwatsuki K, Murakami K, Takigawa M.
    Int J Dermatol; 1995 Nov; 34(11):811-6. PubMed ID: 8543420
    [Abstract] [Full Text] [Related]

  • 22. [Induction of lymphokine activated killer (LAK) and prolongation of its activity by intrasplenic injection of interleukin 2 (IL-2) in combination with tumor necrosis factor (TNF)].
    Nakajima I, Okuno K, Ohnishi H, Shilayama Y, Nakamura T, Hirohata T, Yasutomi M.
    Nihon Geka Gakkai Zasshi; 1990 Oct; 91(10):1548-53. PubMed ID: 2263237
    [Abstract] [Full Text] [Related]

  • 23. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S.
    Cancer Res; 1990 Nov 15; 50(22):7343-50. PubMed ID: 2224862
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A case of malignant haemangioendothelioma showing response to interleukin 2 therapy.
    Inadomi T, Fujioka A, Suzuki H.
    Br J Dermatol; 1992 Oct 15; 127(4):442-3. PubMed ID: 1419766
    [No Abstract] [Full Text] [Related]

  • 27. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
    Marolleau JP, Baccard M, Flageul B, Rybojad M, Laroche L, Vérola O, Brandely M, Morel P, Gisselbrecht C.
    Arch Dermatol; 1995 May 15; 131(5):574-9. PubMed ID: 7741545
    [Abstract] [Full Text] [Related]

  • 28. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 15; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 29. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 30. Spindle cell hemangioendothelioma: successful treatment with recombinant interleukin-2.
    Setoyama M, Shimada H, Miyazono N, Baba Y, Kanzaki T.
    Br J Dermatol; 2000 Jun 01; 142(6):1238-9. PubMed ID: 10848757
    [No Abstract] [Full Text] [Related]

  • 31. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr 01; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

  • 32. [An experimental study on the in vivo induction of lymphokine activated killer (LAK) cells by the continuous infusion of interleukin 2 (IL-2) through the splenic artery].
    Ohnishi H.
    Nihon Gan Chiryo Gakkai Shi; 1988 Dec 20; 23(11):2785-93. PubMed ID: 3266874
    [No Abstract] [Full Text] [Related]

  • 33. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C.
    Eur J Cancer Clin Oncol; 1989 Dec 20; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [Abstract] [Full Text] [Related]

  • 34. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF, Aramendía JM, Alonso G, Foncillas JG, Brugarolas A.
    Rev Med Univ Navarra; 1996 Dec 20; 40(3):6-12. PubMed ID: 9499820
    [Abstract] [Full Text] [Related]

  • 35. Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases.
    Mavligit GM, Zukiwski AA, Gutterman JU, Salem P, Charnsangavej C, Wallace S.
    J Clin Oncol; 1990 Feb 20; 8(2):319-24. PubMed ID: 2405108
    [Abstract] [Full Text] [Related]

  • 36. [A case of Stewart-Treves syndrome--treatment with recombinant interleukin 2 and a review of Japanese literature].
    Nabeya R, Kobayashi M, Fujita M, Yorifuji K, Eguchi N, Okamoto S.
    Nihon Hifuka Gakkai Zasshi; 1990 Sep 20; 100(10):1029-39. PubMed ID: 2266596
    [Abstract] [Full Text] [Related]

  • 37. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA, Mulé JJ.
    Surgery; 1985 Sep 20; 98(3):437-44. PubMed ID: 3898451
    [Abstract] [Full Text] [Related]

  • 38. [The efficacy of recombinant interleukin 2 in local treatment of superficial bladder tumors].
    Fujioka T, Shiraishi M, Tanji S, Sato S, Koike H, Aoki H, Suzuki K, Kumagai K, Banya Y, Kubo T.
    Hinyokika Kiyo; 1988 Dec 20; 34(12):2115-9. PubMed ID: 3266444
    [Abstract] [Full Text] [Related]

  • 39. [Bronchial arterial infusion of lymphokine-activated killer cells stimulated by autologous tumor cells].
    Kimura H, Yamaguchi Y, Obata S, Yusa T, Sekine Y.
    Gan To Kagaku Ryoho; 1988 Aug 20; 15(8 Pt 2):2401-4. PubMed ID: 3137876
    [Abstract] [Full Text] [Related]

  • 40. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
    Ikawa T, Eura M, Fukiage T, Murakami H, Yamasaki S, Fukuda K, Fukushima M, Arishima S, Maehara T, Ishikawa T.
    Gan To Kagaku Ryoho; 1989 Apr 20; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.